Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation currently under clinical investigation in hepatocellular carcinoma (HCC) patients. Our study explored the effects of galunisertib in vitro in HCC cell lines and ex vivo on patient samples. Galunisertib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Serova, Maria, Tijeras-Raballand, Annemilaï, Santos, Célia Dos, Albuquerque, Miguel, Paradis, Valerie, Neuzillet, Cindy, Benhadji, Karim A., Raymond, Eric, Faivre, Sandrine, de Gramont, Armand
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673290/
https://ncbi.nlm.nih.gov/pubmed/26057634
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars